Type 1 IFNs May Mediate Zika Pregnancy Complications

This article originally appeared here.
Share this content:
Type 1 IFNs May Mediate Zika Pregnancy Complications
Type 1 IFNs May Mediate Zika Pregnancy Complications

MONDAY, Jan. 8, 2018 (HealthDay News) -- Type 1 interferons (IFNs) may mediate pregnancy complications in the context of congenital Zika virus (ZIKV) infection, according to a study published in the Jan. 5 issue of Science Immunology.

Laura J. Yockey, from the Yale University School of Medicine in New Haven, Conn., and colleagues examined the role of type 1 IFNs in limiting or mediating ZIKV disease within a model of congenital infection, observed after ZIKV infection of type I IFN receptor knockout (ifnar1−/−) dams mating with wild-type sires, resulting in fetuses with functional type 1 IFN signaling. Pregnant dams carried a mixture of fetuses that expressed or did not express IFN-α/β receptor (IFNAR) (ifnar1+/− and ifnar1−/−) within the same uterus.

The researchers found that the titer of virus replication was higher in the placenta of ifnar1−/− than ifnar1+/−. Only ifnar1+/− fetuses were resorbed after ZIKV infection during early pregnancy; ifnar1−/− littermates continued to develop. IFNAR signaling in the conceptus was found to inhibit development of the placental labyrinth, resulting in abnormal maternal-fetal barrier architecture after ZIKV infection. Exposure of midgestation human chorionic villous explants to type I IFN resulted in altered placental morphology and cytoskeletal rearrangements within the villous core; this was not seen with exposure to type III IFN.

"Our results implicate type I IFNs as a possible mediator of pregnancy complications, including spontaneous abortions and growth restriction, in the context of congenital viral infections," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »